ClinicalTrials.Veeva

Menu

QT-prolongation in Psychiatric Hospitals

C

Catholic University (KU) of Leuven

Status

Completed

Conditions

QT-prolongation

Treatments

Drug: drugs linked with QT-prolongation

Study type

Observational

Funder types

Other

Identifiers

NCT02043925
VF/2010/02

Details and patient eligibility

About

Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug. An ECG is taken before the administration of the new drug and a week after starting the new drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation and blood concentrations of potassium and creatinine are documented.

Enrollment

152 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • inpatient in one of the 6 participating psychiatric hospitals
  • QT-prolonging drug in the medication profile and the doctor prescribes another QT-prolonging drug

Exclusion criteria

  • age < 18 year

Trial design

152 participants in 1 patient group

psychiatric patients treated with QT-prolonging drugs
Treatment:
Drug: drugs linked with QT-prolongation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems